| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 13th July 2020 | Walter V Klemp | 79,227 | Exercise of derivative | $0.00 | |
| 13th July 2020 | Walter V Klemp | 19,292 | Payment by withholding | $0.86 | $16,513.95 |
Moleculin Biotech
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms.
Ticker: MBRX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1659617
Employees: 9
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $17 M (55%)
Other Assets, Current: $436 Th (-17%)
Assets, Current: $20 M (46%)
Property, Plant and Equipment, Net: $238 Th (-24%)
Assets: $31 M (24%)
Accounts Payable, Current: $2 M (-10%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $4 M (4%)
Liabilities: $16 M (62%)
Common Stock, Value, Issued: $60 Th (30%)
Common Stock, Shares, Issued: $60 M (32%)
Additional Paid in Capital, Common Stock: $66 M (20%)
Retained Earnings (Accumulated Deficit): $51 M (0%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $31 M (24%)
Research and Development: $3 M (-49%)
General and Administrative Expenses: $2 M (-52%)
Operating Income/Loss: $5 M (-50%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
